• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Incidence of Late Breast Cancer Recurrence in Women with 10-Year Disease-Free Survival

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • In recent decades, more effective breast cancer treatments have become available, leading to an increase in the prevalence of long-term survivors
  • Approximately 50% of women with early stage breast cancer remain disease-free for at least ten years
  • Pedersen et al. (Journal of the National Cancer Institute, 2021) examined the risk of late breast cancer recurrence up to 32 years later

METHODS:

  • Nationwide cohort study
    • Data derived from Danish administrative and population-based registries
  • Population
    • All women with incident early breast cancer diagnosed during 1987 to 2004
    • 10 years without a recurrence or second cancer
  • Exposures
    • Patient and tumor characteristics
  • Study design
    • 10-year disease-free survivors were followed from 10 years after breast cancer diagnosis until late recurrence, death, emigration, second cancer, or December 2018
    • Late breast cancer recurrence was calculated as incidence rates per 1000 person-years and cumulative incidences
    • Adjusted hazard ratio (HR) was calculated using Cox regression
  • Primary outcome
    • Late breast cancer recurrence

RESULTS:

  • 36,924 women with breast cancer between 1987 and 2004
    • 10-year disease-free survivors: 20,315 women
  • Incidence of late breast cancer recurrence 10 to 32 years after primary diagnosis
    • Total late recurrence cases: 2595 women
    • Incidence rate 15.53 per 1000 person-years (95% CI, 14.94 to 16.14)
    • Cumulative incidence 16.6% (95% CI, 15.8 to 17.5)
  • The following were associated with increased cumulative incidences and hazards for late breast cancer recurrence
    • Tumor size >20 mm
    • Lymph node positive disease
    • Estrogen receptor-positive tumors

CONCLUSION:

  • Late breast cancer recurrence in 10-year disease-free survivors occurred in 16.6% of women 10 to 32 years after primary diagnosis
  • Women who had larger tumors, estrogen-receptor positive tumors, and lymph node involvement were at increased risk
  • The authors state

Our findings suggest that a subset of patients—with larger tumors, positive lymph nodes, or ER-positive disease—are at risk of late recurrence

Such patients may warrant extended surveillance, more aggressive treatment, or new therapies

Our study advocates for further research to characterize the biology underlying the resurgence of breast cancer long after primary diagnosis to inform strategies for prevention, treatment, and effective follow-up programs

Learn More – Primary Sources:

The Incidence of Breast Cancer Recurrence 10-32 Years after Primary Diagnosis

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Breast Cancer Recurrence Risks Following Endocrine Therapy – 20 Years Out
TAILORx Results: Can a Gene-Expression Test Help Determine if Some Women with Breast Cancer Can Safely Avoid Chemotherapy?
BRCA1 & BRCA2 Mutations: What Are the Risks for Developing Breast and Ovarian Cancer?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site